Practice Patterns and Incidence of Febrile Neutropenia in Patients Receiving Triplet Drug Chemotherapeutic Regimens in GUT Cancers: Do We Need to Add WBC Growth Factors? (ForGeT GCSF Study)
The use of GF reduces the rates of FN by approximately 80% in patients receiving mFLOT and mFOLFIRINOX, although incidences of FN are low with these regimens. The incidence of febrile neutropenia was similar with single-dose versus multiday GF in efficacy when administered with mFLOT and mFOLFIRINOX chemotherapy.
Authors
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- Anant Ramaswamy (ORCID: https://orcid.org/0000-0002-8169-4264)
- Mannavi Suman
- Vikas S Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- S. Srinivas (ORCID: https://orcid.org/0000-0001-9981-364X)
- Noorzia Sultana
- Mehak Trikha
- Kapu Venkatesh
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
Publication Details
- Journal
- South Asian Journal of Cancer
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1055/s-0044-1789590
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00